Biovie (BIVI) Income from Continuing Operations (2013 - 2026)
Biovie (BIVI) posted Income from Continuing Operations of 5270299.0 for Q1 2026, up 13.17% sequentially from 6069475.0 in Q4 2025, and down 89.01% YoY from 47941346.71 in Q1 2025.
Biovie (BIVI) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Biovie has reported Income from Continuing Operations for 12 years, with the latest figure at 5270299.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 89.01% year-over-year to 5270299.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 19960016.0 (down 3.08% YoY) and the FY2025 annual result came in at 17911585.0, up 45.73% from the prior year.
- Income from Continuing Operations climbed to 5270299.0 in Q1 2026 per BIVI's latest filing, from 6069475.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 2788418.0 in Q1 2025 and troughed at 15687002.0 in Q4 2022.
- A 5-year average of 7810272.47 and a median of 7156953.0 in 2024 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 93.85% in 2022, down 189.73% in 2022.
- Over 5 years, Income from Continuing Operations stood at 15687002.0 in 2022, then soared by 46.44% to 8401445.0 in 2023, then grew by 14.81% to 7156953.0 in 2024, then climbed by 15.19% to 6069475.0 in 2025, then gained by 13.17% to 5270299.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 5270299.0, 6069475.0, and 5131101.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Biovie | 14.17 Mn | 14.17 Mn | - | -5.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.65 Mn |
| Mar 31, 2026 | -5.27 Mn |
| Dec 31, 2025 | -6.07 Mn |
| Sep 30, 2025 | -5.13 Mn |
| Jun 30, 2025 | -3.49 Mn |
| Mar 31, 2025 | -2.79 Mn |
| Dec 31, 2024 | -7.16 Mn |
| Sep 30, 2024 | -4.48 Mn |
| Jun 30, 2024 | -4.94 Mn |
| Mar 31, 2024 | -8.95 Mn |
| Dec 31, 2023 | -8.40 Mn |
| Sep 30, 2023 | -10.71 Mn |
| Jun 30, 2023 | -9.11 Mn |
| Mar 31, 2023 | -15.04 Mn |
| Dec 31, 2022 | -15.69 Mn |
| Sep 30, 2022 | -10.42 Mn |
| Jun 30, 2022 | -8.09 Mn |
| Mar 31, 2022 | -7.04 Mn |
| Dec 31, 2021 | -5.41 Mn |
| Sep 30, 2021 | -5.54 Mn |